https://endpts.com/in-reversal-sarepta-to-face-fdas-panel-of-outside-experts-on-duchenne-gene-therapy/?u=9072b1fe-e439-4432-ace6-17b4dc5ff6e8&s=email&c=ead60ced-5061a111-c4a58490&utm_medium=email&utm_campaign=382%20-%20Amgen%20trims%20headcount%20again%20Surprise%20court%20order%20keeps%20IP%20dispute%20alive%20against%20Moderna%20Basic&utm_content=382%20-%20Amgen%20trims%20headcount%20again%20Surprise%20court%20order%20keeps%20IP%20dispute%20alive%20against%20Moderna%20Basic+CID_7ea062ca2b04f6cdf8797b4c3e2e8a11&utm_source=ENDPOINTS%20emails&utm_term=In%20reversal%20Sarepta%20to%20face%20FDAs%20panel%20of%20outside%20experts%20on%20Duchenne%20gene%20therapy
The Sarepta approval is not a done deal it seems.
- Forums
- ASX - By Stock
- PER
- Fresh Start
Fresh Start, page-44
-
- There are more pages in this discussion • 62 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.66M |
Open | High | Low | Value | Volume |
10.5¢ | 10.5¢ | 9.8¢ | $58.09K | 574.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 38503 | 10.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.5¢ | 194063 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 38503 | 0.100 |
2 | 110101 | 0.099 |
2 | 108491 | 0.098 |
1 | 30927 | 0.097 |
1 | 10004 | 0.096 |
Price($) | Vol. | No. |
---|---|---|
0.105 | 194063 | 5 |
0.110 | 254663 | 3 |
0.115 | 1334300 | 6 |
0.120 | 381142 | 9 |
0.125 | 110429 | 2 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |